Multidose pre-filled pen for subcutaneous use
Active substance: Tirzepatide
Dispensing category: Prescription only, Group II
Multidose pre-filled pen for subcutaneous use
Each pen contains 4 fixed doses; one dose is taken weekly.
Mounjaro (tirzepatide) is a prescription medication for adults with type 2 diabetes,
Used for:
control of blood sugar (glucose) levels. The medication is also used for the treatment of obesity or overweight in adults (BMI at least 27 kg/m²) who have weight-related health problems (e.g., prediabetes, type 2 diabetes, high blood pressure, blood lipid disorders, etc.)
Contains: tirzepatide, a dual GIP and GLP-1 receptor agonist that belongs to a new class of medications called incretin mimetics.
Each pen contains four fixed doses of the indicated strength, meaning, for example: a 15 mg pen contains a total of 60 mg of tirzepatide (4 doses × 15 mg), each dose 0.6 mL. Patients administer one dose weekly, therefore each pen is designed for one month of use.
How does Mounjaro work?
Mounjaro is the first GIP and GLP-1 receptor agonist that works on glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. Mounjaro lowers blood sugar, helps the pancreas produce more insulin, reduces the amount of sugar produced by the liver, and slows the rate at which food leaves the stomach, which helps prolong the feeling of fullness and may reduce food intake. All of this supports stable blood sugar levels throughout the day.
Mounjaro side effects:
The most common side effects of Mounjaro include: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain, affecting 5% or more of patients.
Stop using this medication and seek emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing.
Call your doctor if you have: severe stomach problems; gallbladder problems with symptoms; stomach pain after eating; kidney problems with reduced or absent urination; swelling of the feet; fatigue or shortness of breath.
This is not a complete list of side effects; others may occur. Call your doctor about any side effects.
Do not use this medicine if:
you have or have a family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC)
you have an endocrine condition called multiple endocrine neoplasia syndrome type 2
you are allergic to tirzepatide
you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
Inform your doctor if you have ever had: pancreatic problems; kidney disease.
Pregnancy: Inform your doctor if you are pregnant or planning to become pregnant while using this medication.
This medication may make birth control pills less effective.
How to use Mounjaro
Inject once weekly in the abdomen, thigh, or upper arm at any time of day.
Always try to use it on the same day each week.
Remember: each pen contains four doses of the indicated strength.
One dose per week means one pen equals a one-month supply.
Mounjaro dosing information:
Usual adult dose for type 2 diabetes:
Initial dose: 2.5 mg subcutaneously once weekly.
After 4 weeks: increase to 5 mg subcutaneously once weekly.
If additional glycemic control is needed: increase the dose in 2.5 mg increments after at least 4 weeks at the current dose.
Maximum dose: 15 mg subcutaneously once weekly.
If necessary, the doctor may increase the dose to 7.5 mg, 10 mg, 12.5 mg, or 15 mg once weekly.
Do not change your dose unless your doctor advises you to.
Storage conditions:
Unused pen should be stored in the refrigerator at 2°C to 8°C (do not freeze).
An unopened pen stored in the refrigerator is valid until the expiration date.
Storage after starting use of the pen:
You may store it at room temperature (up to 30°C) for up to 30 days.
Keep away from heat and sunlight.
Discard after 30 days from first use, even if medicine remains.
Always use Mounjaro under medical supervision.
Company: Eli Lilly and Company
Lilly USA, LLC Indianapolis, IN 46285, USA.
